Alliance Pharmaceuticals

Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB
Telephone: +44 (0)1249 466 966
Fax: +44 (0)1249 466 977
WWW: http://www.alliancepharma.co.uk
Medical Information e-mail: medinfo@alliancepharma.co.uk
Summary of Product Characteristics last updated on the eMC: 04/06/2008
SPC Biorphen

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 04/06/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   28-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.4 - Avoid abrupt withdrawal of treatment - has been added.
Updated on 19/06/2007 and displayed until 04/06/2008
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   06/2007
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Section 4.3 - the following sentence was added

Hypersensitivity to orphenadrine, or to any of the excipients.

 
Section 4.4- the following sentence was added

 Contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.

Updated on 07/07/2003 and displayed until 19/06/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 16/01/2003 and displayed until 07/07/2003
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 29/04/2002 and displayed until 16/01/2003
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 16/07/2001 and displayed until 29/04/2002
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 12/07/2001 and displayed until 16/07/2001
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 19/02/2001 and displayed until 12/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/03/2000 and displayed until 19/02/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 06/03/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   orphenadrine


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk